Abbott Launches Similac® 360 Total Care® with Exclusive Blend of Five HMO Prebiotics and Designed to Support the Immune System, Digestive Health and Brain Development

 
 

Abbott (NYSE: ABT) today announced the launch of Similac 360 Total Care, the company's next generation of infant formula with HMOs, major prebiotics structurally identical to those found in human breast milk. Similac 360 Total Care is the first and only infant formula in the U.S. with a blend of five different HMOs, previously only found together in breast milk. This formula is designed to provide nutrition to support the whole baby's health and development, including the developing immune system, digestive system and brain.

 

Abbott scientists have been studying HMOs in breast milk for more than two decades. While breast milk is the gold standard of infant nutrition, nearly 75% of parents introduce infant formula within the first six months of a baby's life for a variety of reasons. Abbott supports parents, whatever their feeding choice. Now with the introduction of Similac 360 Total Care, parents can use a formula with a blend of five specific HMOs, previously only available to infants through breast milk.

 

"While nothing can replace the benefits of breast milk where HMOs are naturally abundant, some parents cannot or choose not to breastfeed, which makes infant formula the only suitable, nutritionally complete alternative for babies," said Rachael Buck , Ph.D., senior research fellow at Abbott. "Now, after delivering the first infant formula with HMOs in 2016, we are delivering our closest formula to breast milk ever, further working to narrow the gap between breast milk and formula so we can give babies the building blocks they need to learn, grow and thrive."

 

The introduction of Similac 360 Total Care is part of Abbott's ongoing commitment to support health from infancy onward. Through ongoing research, investment and innovation, this commitment supports Similac's Promises Project , the promise to support all parents regardless of their feeding choices.

 

"Parents strive to make the best decisions for their children every day," said Shawn Millerick , vice president of Pediatric Nutrition at Abbott. "We have made a promise to parents to provide them with our very best, scientifically-backed products like Similac 360 Total Care, as well as resources and information to support them and their feeding choices."

 

Similac 360 Total Care will be available online at www.AbbottStore.com , and at major retailers online and in-store locations, including Amazon, Walmart and Target. For more information on the science of Similac 360 Total Care and support for parents, visit Similac.com .

 

  About Abbott
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 109,000 colleagues serve people in more than 160 countries.

 

Connect with us at www.abbott.com , on LinkedIn at www.linkedin.com/company/abbott-/ , on Facebook at https://www.facebook.com/Abbott and on Twitter @AbbottNews .

 

  1 HMOs in Similac 360 Total Care are not from human milk
2 The five specific HMOs include 2'-FL, 3-FL , 3'-SL,  6'- SL, and LNT across fucosylated, sialylated and acetylated categories of HMOs.

 

 

 

 Cision View original content: https://www.prnewswire.com/news-releases/abbott-launches-similac-360-total-care-with-exclusive-blend-of-five-hmo-prebiotics-and-designed-to-support-the-immune-system-digestive-health-and-brain-development-301425834.html  

 

SOURCE Abbott

 
 

News Provided by PR Newswire via QuoteMedia

The Conversation (0)
illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians.

BlinkLab states in its Wednesday (March 12) release that the study is the largest digital diagnostic trial for autism in the US, with its aim being to support the early detection of developmental conditions like autism.

The first patient test took place at PriMED Clinical Research in Dayton, Ohio. PriMED, a division of PriMED Physicians, is one of two clinical sites selected for the study’s initial phase, which is targeting 100 patients.

Keep reading...Show less
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at enhancing remote pregnancy monitoring and expanding the range of health data available to expectant mothers and their healthcare providers.

Keep reading...Show less
Cardiologist wearing virtual reality glasses.

2 Biggest Medical Device ETFs in 2025

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.

Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.

In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.

Keep reading...Show less
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the deployment of Technegas® in up to 169 nuclear medicine departments across HCA’s extensive network.1

Keep reading...Show less
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries Commence

Download the PDF here.

Female doctor with clipboard talking to smiling female patient at hospital.

Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities

The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities.

The groundbreaking developments in antifungal treatments specifically targeting women's health issues present a substantial market potential, resulting in rising investor interest in this rapidly evolving sector.

Despite comprising half the global population, women face unique health challenges that have historically received insufficient attention and investment. Among these health challenges, vaginal candidiasis stands out as a persistent and widespread issue affecting millions of women worldwide.

Keep reading...Show less

Latest Press Releases

Related News

×